Categories AlphaGraphs, Analysis, Earnings, Retail
Earnings preview: What to expect when PepsiCo reports Q2 2019 results?
PepsiCo Inc. (NASDAQ: PEP) is scheduled to report second quarter 2019 earnings results on Tuesday, July 9, before market open. Earnings are estimated to decline 7.5% year-over-year to $1.49 per share while revenues are projected to increase 2% to $16.4 billion. Over the trailing four quarters, the company has topped earnings estimates three times.
PepsiCo’s topline results are expected to benefit from the strong performance of the snacks business, which continues to deliver solid revenues. The beverages business is also slightly gaining momentum and this could add to the gains in the quarter. However, the company continues to see weakness in the Quaker Foods North America segment which is likely to dent the topline.
PepsiCo continues to boost its strong product portfolio through innovation and strategic partnerships. The company recently teamed up with Lavazza to launch iced coffee in the UK. PepsiCo’s diversification efforts through various acquisitions and partnerships are likely to pay off in driving growth going forward.
Although the company is dealing with changing customer preferences in the US, it is seeing growth outside the US, particularly in emerging markets. This growth is likely to prove beneficial to the results in the second quarter. PepsiCo has also been taking measures to reduce costs and this is likely to help profitability.
In the first quarter of 2019, PepsiCo beat revenue and earnings estimates. Both revenue and adjusted EPS grew 3% year-over-year. The company posted revenue growth across all its segments, barring Quaker Foods North America and AMENA.
For the full year of 2019, PepsiCo expects organic revenue to grow 4% and core constant currency EPS to decline 1%. PepsiCo’s shares have gained 19% thus far this year and 23% over the trailing 52 weeks.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on